Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,187
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
CISPLATIN, CARBOPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, GEMCITABINE, IMJUDO 20 mg/ml concentrate for solution for infusion., INFLIXIMAB, GEMCITABINE
AstraZeneca AB
Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer
1 trial -
CISPLATIN, GEMCITABINE, INFLIXIMAB, Rilvegostomig, IMFINZI 50 mg/mL concentrate for solution for infusion., DS-8201a, MYCOPHENOLATE MOFETIL
AstraZeneca AB
Advanced HER2-expressing Biliary Tract Cancer
1 trial -
CISPLATIN, INFLIXIMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., GEMCITABINE, MYCOPHENOLATE MOFETIL
AstraZeneca AB
First-line patients with advanced biliary tract cancers (BTC)
1 trial -
CISPLATIN, TAGRISSO 40 mg film-coated tablets, Datopotamab deruxtecan, TAGRISSO 80 mg film-coated tablets, CARBOPLATIN, PEMETREXED
AstraZeneca AB
Non squamous non-small cell lung cancer (NSCLC)
1 trial -
CYCLOPHOSPHAMIDE, PACLITAXEL, MYCOPHENOLATE MOFETIL, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE, CAPECITABINE, EPIRUBICIN, IMFINZI 50 mg/mL concentrate for solution for infusion., CAPECITABINE, CARBOPLATIN, INFLIXIMAB, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL, CYCLOPHOSPHAMIDE, PEMBROLIZUMAB, Datopotamab deruxtecan, Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets, MYCOPHENOLATE MOFETIL, DOXORUBICIN
AstraZeneca AB
Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer
1 trial -
Calquence 100 mg hard capsules
AstraZeneca AB
Chronic lymphocytic leukemia
1 trial -
Capivasertib, Faslodex 250 mg solution for injection., Placebo to Capivasertib, Capivasertib
AstraZeneca AB
Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer
1 trial -
Capivasertib, Placebo for capivasertib film-coated tablet for oral use, ABIRATERONE ACETATE, Capivasertib
AstraZeneca AB
Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN deficiency
1 trial -
Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Capecitabine Accord 500 mg film-coated tablets, Inflectra 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., The Placebo is formulated as 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0., Fluorouracil Injection, 50 mg/ml, solution for injection, Mycophenolate Mofetil Accord 250 mg capsules, Capecitabine Accord 150 mg film-coated tablets
AstraZeneca AB
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
1 trial -
DAPAGLIFLOZIN, Zibotentan + Dapagliflozin, Zibotentan + Dapagliflozin
AstraZeneca AB
Chronic Kidney Disease and High Proteinuria
1 trial -
DOCETAXEL, Inflectra 100 mg powder for concentrate for solution for infusion, Mycofit, 250 mg, kapsułki twarde, DOCETAXEL, INFLIXIMAB, Remsima 100 mg powder for concentrate for solution for infusion, Ceralasertib, MYCOPHENOLATE MOFETIL, Docetaxel Hikma 80 mg/4 ml Konzentrat zur Herstellung einer Infusionslösung, DOCETAXEL, MYCOPHENOLATE MOFETIL, IMFINZI 50 mg/mL concentrate for solution for infusion.
AstraZeneca AB
Advanced or Metastatic Non-Small Cell Lung Cancer
1 trial -
DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, PACLITAXEL, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, TOPOTECAN, AZD5335, MIRVETUXIMAB SORAVTANSINE
AstraZeneca AB
Advanced Platinum-resistant Epithelial Ovarian Cancer
1 trial -
DURVALUMAB, MYCOPHENOLIC ACID , Padcev 20 mg powder for concentrate for solution for infusion, TREMELIMUMAB, Padcev 30 mg powder for concentrate for solution for infusion, INFLIXIMAB
AstraZeneca AB
Bladder Cancer
1 trial -
DURVALUMAB, Savolitinib, MYCOPHENOLATE MOFETIL, Sutent 12.5 mg hard capsules, Sutent 25 mg hard capsules, Sutent 12.5 mg hard capsules, INFLIXIMAB, Sutent 25 mg hard capsules
AstraZeneca AB
MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma
1 trial -
Datopotamab deruxtecan, DOCETAXEL
AstraZeneca AB
TROP2 NMR-positive advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.
1 trial -
Datopotamab deruxtecan, MYCOPHENOLATE MOFETIL, PEMBROLIZUMAB, INFLIXIMAB, CAPECITABINE, IMFINZI 50 mg/mL concentrate for solution for infusion.
AstraZeneca AB
Stage I-III Triple-negative Breast Cancer with residual invasive disease after neoadjuvant systemic therapy.
1 trial -
Datopotamab deruxtecan, Rilvegostomig, MYCOPHENOLATE MOFETIL, INFLIXIMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion
AstraZeneca AB
Locally-advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
1 trial -
ERIBULIN MESYLATE, VINORELBINE, GEMCITABINE, CAPECITABINE, CAPECITABINE, Datopotamab deruxtecan
AstraZeneca AB
"Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy"
1 trial -
Esomeprazole Magnesium, NEXIUM 10 mg gastro-resistant granules for oral suspension, sachet, Esomeprazole Magnesium
AstraZeneca AB
Erosive Esophagitis
1 trial -
FIBRINOGEN, HUMAN, RIVAROXABAN , APIXABAN , ETAMSYLATE , TRANEXAMIC ACID , -, PROTAMINE , -, ERYTHROCYTES , AMINOMETHYLBENZOIC ACID , -, AMINOCAPROIC ACID , Ondexxya 200 mg powder for solution for infusion, EDOXABAN , -
AstraZeneca AB
Reversal of anticoagulation effect in patients on a FXa inhibitor (apixaban, rivaroxaban, or edoxaban) who require urgent surgery or procedure, and who have a major risk of bleeding.
1 trial -
Forxiga 10 mg film-coated tablets, Baxdrostat Placebo, Baxdrostat, Baxdrostat, Baxdrostat
AstraZeneca AB
Prevention of Heart failure
1 trial -
GEMCITABINE, GEMCITABINE, INFLIXIMAB, DURVALUMAB, MYCOPHENOLATE MOFETIL, CISPLATIN
AstraZeneca AB
Patients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladder
1 trial -
GEMCITABINE, INFLIXIMAB, CISPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion, MYCOPHENOLATE MOFETIL, Rilvegostomig
AstraZeneca AB
Biliary Tract Cancer
1 trial -
Gazyvaro 1,000 mg concentrate for solution for infusion., Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Calquence 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Calquence 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Calquence 100 mg hard capsules, Venclyxto 10 mg film-coated tablets, Calquence 100 mg hard capsules
AstraZeneca AB
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources